Amy Pitts
Family · Newport, TNNPI 1427207570
Payments from drug & device makers
Across 466 payments — averaging $15.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$670
- AstraZeneca$662
- Boehringer Ingelheim$490
- GSK$447
- Pfizer$435
- plus $3K from 33 others
What the payments were for
- Food & beverage$7,243100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 116 | $1,601 |
| AbbVie(2 entities) | 46 | $670 |
| AstraZeneca | 33 | $662 |
| Boehringer Ingelheim | 35 | $490 |
| GSK | 37 | $447 |
| Pfizer | 30 | $435 |
| Sumitomo Pharma America, Inc. | 25 | $365 |
| Novartis | 14 | $214 |
| Lilly USA, LLC | 11 | $180 |
| Mylan Specialty L.p. | 9 | $160 |
| Amarin Pharma, Inc. | 9 | $154 |
| Johnson & Johnson | 8 | $137 |
| E.r. Squibb & Sons, L.L.C. | 9 | $135 |
| Bayer | 8 | $134 |
| Merck | 8 | $114 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $98 |
| Silk Road Medical, Inc. | 1 | $98 |
| Medtronic | 1 | $97 |
| Amgen | 7 | $95 |
| Sanofi-aventis U.S. LLC | 6 | $94 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $92 |
| Kowa Pharmaceuticals America, Inc. | 5 | $86 |
| Astellas Pharma US Inc | 5 | $82 |
| Viatris Specialty LLC | 3 | $75 |
| Esperion Therapeutics, Inc. | 4 | $70 |
| UCB, Inc. | 3 | $67 |
| Phathom Pharmaceuticals, Inc. | 3 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $64 |
| Axsome Therapeutics, Inc. | 2 | $38 |
| Corcept Therapeutics | 2 | $37 |
| Supernus Pharmaceuticals, Inc. | 2 | $35 |
| Dexcom, Inc. | 2 | $26 |
| Eisai Inc. | 2 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Corium, LLC | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Antares Pharma, Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $12 |
How this compares
$7,243 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 120 | $141,030 |
| EliquisApixaban | 105 | $101,275 |
| JardianceEmpagliflozin | 80 | $82,769 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 68 | $76,984 |
| MounjaroTirzepatide | 73 | $74,420 |
| Tresiba Flextouch U-200Insulin Degludec | 48 | $39,846 |
| LinzessLinaclotide | 32 | $33,111 |
| TrulicityDulaglutide | 29 | $32,994 |
| RybelsusSemaglutide | 23 | $31,518 |
| GlyxambiEmpagliflozin/Linagliptin | 30 | $22,822 |
| Spiriva RespimatTiotropium Bromide | 26 | $21,457 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $18,487 |
| Repatha SureclickEvolocumab | 11 | $18,120 |
| XareltoRivaroxaban | 24 | $17,556 |
| EntrestoSacubitril/Valsartan | 16 | $16,719 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,601 | $172,548143 claims |
| Boehringer IngelheimJardiance, Glyxambi, Spiriva Respimat, Stiolto Respimat | $490 | $133,179148 claims |
| Lilly USA, LLCMounjaro, Trulicity | $180 | $107,413102 claims |
| PfizerEliquis, Paxlovid | $435 | $104,133138 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $94 | $76,98468 claims |
| AbbVieLinzess, Synthroid | $670 | $36,88381 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $662 | $27,78544 claims |
| GSKTrelegy Ellipta, Shingrix | $447 | $18,91135 claims |
| Johnson & JohnsonXarelto | $137 | $17,55624 claims |
| NovartisEntresto | $214 | $16,71916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.
Other family in Newport
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.